New partners for Phase 2 trial of next-gen lithium therapy AL001 - Alzheimer's News Today
Alzamend Neuro partners with Massachusetts General Hospital for a Phase 2 trial of AL001, an oral therapy for Alzheimer’s-related dementia. The trial aims to determine the minimum effective dose and safety profile of AL001, a novel lithium-delivery system, compared to marketed lithium. Preclinical studies show AL001 prevents cognitive impairment and improves learning and memory in mouse models of Alzheimer’s. A completed Phase 1/2 trial suggests AL001 is well-tolerated and achieves similar blood lithium levels to marketed lithium at lower doses.
Related Clinical Trials
Reference News
Alzamend Neuro partners with Massachusetts General Hospital for a Phase 2 trial of AL001, an oral therapy for Alzheimer’s-related dementia. The trial aims to determine the minimum effective dose and safety profile of AL001, a novel lithium-delivery system, compared to marketed lithium. Preclinical studies show AL001 prevents cognitive impairment and improves learning and memory in mouse models of Alzheimer’s. A completed Phase 1/2 trial suggests AL001 is well-tolerated and achieves similar blood lithium levels to marketed lithium at lower doses.